share_log

Longevity Biomedical, Inc. And Denali Capital Acquisition Corp. Announce Business Combination

Benzinga Real-time News ·  Jan 26, 2023 06:35
  • Longevity Biomedical is focused on developing and acquiring new technologies spanning therapeutics, health monitoring and digital health solutions to become a leading provider of longevity-related products and services designed to increase health span for the rapidly growing global aging population.
  • Late-stage, diversified pipeline of therapeutic candidates across ophthalmology, cardiovascular disease and soft tissue reconstruction and repair.
  • Total proceeds expected to bring minimum pro forma cash balance of $30 million with cash runway into 2025.
  • Near-term clinical milestones include Phase 3 start for LBI-201 for Ischemic stroke, Phase 2 data for LBI-101 for soft-tissue reconstruction, Phase 2 start for LBI-001 in retinal vein occlusion, and completion of preclinical and formulation studies for LBI-002 in corneal blindness.
  • Seasoned management team of medtech and biopharmaceutical veterans with track record of acquiring, developing and commercializing novel technologies.
  • Post-combination company to list on Nasdaq under ticker symbol "LBIO."
  • Business combination expected to close in Q2 2023.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment